Company
AdAlta Ltd
ASX:1AD
AdAlta is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers. The company's “East to West” cellular immunotherapy strategy is the primary driver of future growth and value creation initiatives.
45 stories
Healthcare stocks maintain clinical momentum in 2023’s March quarter
Year-to-date figures indicate the healthcare sector is up 6.13%, while the XHJ index has jumped 9.09% since this time last year.
AdAlta eyes AD-214 application in kidney and lung fibrosis
“FY22 was a busy period and one which saw AdAlta deliver a number of important value-building milestones via our AD-214 program, and in the last few weeks, we’ve reported a substantial amount of new data for AD-214, our first in class anti-
AdAlta expands disease areas for AD-214 applications
The company will prioritise injectable delivery of AD-214 for lung, kidney or eye fibrosis for development.
AdAlta receives additional funds from tax incentive refund
The company has been given an extra $495,454 as part of the Research and Development Tax Incentive taking its total refund to $2,077,927.
AdAlta and GPCR Therapeutics collaborate on novel cancer treatment approach
CXCRF is overexpressed in multiple cancers, so finding an effective inhibitor represents a multi-billion-dollar opportunity.
AdAlta receives $1.58 million in R&D tax refund
The company is likely to use part of the rebate for a partial repayment of the $4 million non-dilutive financing facility agreement it has with the Victorian Government.
AdAlta modifies AD-214 development program timeline to maximise partner opportunities and extend cash runway
“While we have been focused on speed to clinical trials, it is now prudent that we make final decisions about incurring the significant costs of manufacturing and toxicology with the fullest possible data and partnering information in hand,
AdAlta receives European patent protection until 2036
AdAlta’s CEO and managing director Dr Tim Oldham said: “Grant of this European patent means AD-214 now has patent protection until 2036 in the eight largest pharmaceutical markets in the world: US, Japan, China, Germany, France, Italy, Spai
AdAlta attracts buy recommendation and a 12-month price target of A$0.25 from Lodge Partners
AdAlta has been valued at A$78.5 million, which is reasonable given its pathway to a Phase II trial in the foreseeable future, according to Lodge Partners.
AdAlta secures patent for AD-214 i-body treatment from Indian Patent Office
“India is a significant pharmaceutical market in its own right and is also a leading manufacturing location for biologic drugs and biosimilars (or generic biologics). This patent expands the protected market for AD-214 and provides addition
AdAlta finalises preclinical development program for inhaled version of anti-fibrotic drug, AD-214
Work to optimise a formulation of AD-214 for nebulisation and inhalation is expected to be completed in parallel with preclinical studies, enabling large animal toxicology studies to be initiated in the March quarter of 2023.
The smart money in medicine: combatting fibrosis
"Most physicians today agree that fibrosis is going to be treated by multiple therapies in combination, much like cancer,” said AdAlta CEO Tim Oldham.
AdAlta receives $1.6 million second tranche of Victorian Government’s R&D cash flow loan
This brings the total funds secured under the research and development cash flow loan initiative to the maximum amount of $4 million.
AdAlta granted Chinese patent protecting idiopathic pulmonary fibrosis therapy AD-214
The company adds the Chinese patent to patents in Australia, the US, Japan and Singapore, and is now targeting other major markets including the EU and India.
AdAlta raises $1.5 million in entitlement offer, funds will progress four pipeline programs
“This funding expands the strategic options available to the company for continued development and partnering of both AD-214 and the i-body platform. We are grateful to our existing shareholders who contributed strongly to the entitlement o
AdAlta reports busy quarter, including cash support for inhaler delivery of its flagship therapy
“We are grateful for the support of existing and new shareholders who participated in our A$3.75 million placement, and for ongoing support for the development of our inhaled form of AD-214,” Oldham said.
AdAlta’s AD-214 treatment judged to have “immense untapped potential” by Pitt Street Research, price target of A$0.27
“We continue to strongly believe in AdAlta’s prospects and are retaining our valuation range based on a probability-weighted discounted cash flow (DCF) approach at A$0.27 per share base case and A$0.49 per share bull case,” says Pitt Street
AdAlta raises $3.75 million to progress key development milestones in 2022
“This funding reinforces AdAlta’s existing cash reserves as we proceed towards key development milestones planned for AD-214 and our partnered programs during the first half of 2022,” says chair.
The Dominos are set up in Japan, RBA backs central crypto, but the ASX is lower
Domino's Group CEO Don Meij said, “Less than three years ago we operated 550 stores and were not present in more than 10 prefectures. We highlighted that our business model at the time did not allow us to reach some of these territories – t
AdAlta's inhaled fibrosis drug AD-214 passes first development milestone with successful nebulisation
"The results of these studies support AD-214 being delivered by inhalation without losing its ability to bind to CXCR4 and at particle sizes with potential to travel to the furthest reaches of the lungs that are most affected by IPF," says
AdAlta presents ‘proof of principle’ data for i-body CAR-T combination at Annual General Meeting
“We are very pleased to share the proof of principle data that so excited us about the potential of this collaboration. We look forward to first experimental results on agreed targets under the collaboration in the first half of next year,"
AdAlta granted second US patent for i-body platform treatment AD-214
“This second patent strengthens AdAlta’s patent portfolio and in particular provides protection for AD-214 in one of the largest pharmaceutical and pulmonary fibrosis markets in the world. Strong intellectual property protection is essentia
AdAlta building pipeline using proprietary i-body technology headlined by lead asset AD-214
The clinical-stage drug development company aims to use its unique i-body technology to create multiple novel therapeutics for debilitating diseases that have proven difficult to drug with traditional antibodies.
AdAlta appoints Spark Plus to engage Southeast Asian investors
The clinical-stage drug development company is using its proprietary i-body technology to solve challenging drug targeting problems and generate a promising new class of single-domain antibody protein therapeutics with the potential to trea
AdAlta will outline fibrosis treatment progress during Proactive CEO Sessions
The i-body technology platform of AdAlta is initially focused on treating fibrotic diseases, such as IPF.
AdAlta’s $4.25 million placement brings lead drug candidate closer to the clinic
Idiopathic Pulmonary Fibrosis (IPF) is an irreversible, unpredictable and incurable disease.